CalciMedica (NASDAQ:CALC) Trading Down 2.1% - Time to Sell?

CalciMedica Inc. (NASDAQ:CALC - Get Free Report) traded down 2.1% during trading on Tuesday . The company traded as low as $5.55 and last traded at $5.73. 44,801 shares were traded during mid-day trading, a decline of 51% from the average session volume of 92,307 shares. The stock had previously closed at $5.85.Wall Street Analysts Forecast GrowthSeparately, Weiss Ratings reissued a "sell (d-)" rating on shares of CalciMedica in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $16.00.Check Out Our Latest Stock Report on CalciMedicaCalciMedica Stock PerformanceThe company has a debt-to-equity ratio of 1.39, a quick ratio of 4.04 and a current ratio of 4.03. The company has a market capitalization of $82.56 million, a price-to-earnings ratio of -3.54 and a beta of 0.58. The firm has a 50-day simple moving average of $4.12 and a two-hundred day simple moving average of $3.24. CalciMedica (NASDAQ:CALC - Get Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.02. On average, sell-side analysts anticipate that CalciMedica Inc. will post -2.21 EPS for the current fiscal year. Institutional Trading of CalciMedicaLarge investors have recently modified their holdings of the stock. Stonehage Fleming Financial Services Holdings Ltd purchased a new position in CalciMedica in the third quarter valued at $165,000. Meritage Portfolio Management increased its holdings in CalciMedica by 33.8% during the 3rd quarter. Meritage Portfolio Management now owns 61,539 shares of the company's stock worth $189,000 after purchasing an additional 15,539 shares during the period. Sheets Smith Investment Management acquired a new stake in CalciMedica in the 3rd quarter valued at about $157,000. Cetera Investment Advisers boosted its stake in shares of CalciMedica by 33.1% in the 2nd quarter. Cetera Investment Advisers now owns 36,385 shares of the company's stock valued at $58,000 after buying an additional 9,045 shares during the period. Finally, Sound View Wealth Advisors Group LLC acquired a new position in shares of CalciMedica during the second quarter worth about $32,000. CalciMedica Company Profile (Get Free Report)CalciMedica, Inc NASDAQ: CALC is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses. The company's lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.Featured ArticlesFive stocks we like better than CalciMedicaDo not delete, read immediatelyThe Crash Has Already Started (Most Just Don’t See It Yet)ALERT: Drop these 5 stocks before January 2026![No Brainer Gold Play]: “Show me a better investment.”INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in CalciMedica Right Now?Before you consider CalciMedica, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CalciMedica wasn't on the list.While CalciMedica currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here